The biological clock in parkinson’s disease: mechanisms and chronotherapy Authors: Hong Liu, Hao Ling, Kangchao Sun, Kun Yang, Wenzhen Du, Yuxiu Ma, Yaru Wang, Kai Wang, Ying Liu, Long Niu Published: 2026 ABSTRACT AbstractCircadian disruption is increasingly recognized as a significant contributor to Parkinson’s disease (PD) pathogenesis and progression. From a chronobiological perspective, this review synthesizes relevant mechanisms, preclinical/clinical evidence, and highlights chronotherapy’s potential in optimizing PD treatment efficacy, reducing side effects, and enabling precision management.Subject terms: Diseases, Neurology, Neuroscience Introduction Parkinson’s disease (PD) stands as the second most prevalent neurodegenerative disorder globally, characterized by the progressive loss of dopaminergic neurons and the accumulation of α-synuclein1,2. Its burden is escalating with an aging population, underscoring an urgent need for innovative therapeutic strategies3. Concurrently, the circadian system—an endogenous time-keeping mechanism that regulates physiology and behavior across a 24-hour cycle—has emerged as a focal point in neuroscience4, with growing evidence linking its disruption to PD pathogenesis. It has emerged as a critical yet underexplored aspect in brain health. A growing body of evidence suggests that circadian disruption may play a significant role in PD pathogenesis and progression, rather than being merely a secondary consequence of the disease5,6. However, the precise mechanisms linking circadian dysfunction to PD pathophysiology remain incompletely understood and are an area of active investigation. Extensive research has begun to delineate specific links between circadian biology and PD. At the molecular level, core clock genes govern the rhythmic expression of pathways involved in oxidative stress, neuroinflammation, and protein homeostasis, processes central to neurodegeneration7. Notably, circadian rhythms influence the dynamics of α-synuclein and key neurotransmitter systems, including dopamine and melatonin. Clinically, disruptions in sleep-wake cycles, rest-activity rhythms, and hormonal profiles are pervasive in PD patients and often precede overt motor symptoms8. This has spurred therapeutic exploration. Interventions such as timed light therapy, melatonin administration, and physical exercise have been investigated for their potential to alleviate both motor and non-motor symptoms by targeting the circadian system9–12. Collectively, these approaches fall under the umbrella of chronotherapy—a therapeutic strategy that leverages circadian biology to optimize clinical outcomes. Chronotherapy encompasses two complementary dimensions: (i) chronopharmacology, which aligns drug administration with endogenous rhythms to maximize efficacy and minimize toxicity; and (ii) circadian restoration, which aims to reset or strengthen disrupted circadian oscillators through zeitgeber-based interventions. This framework provides a rationale for the interventions discussed above and sets the stage for evaluating their clinical evidence. However, the translation of these insights into clinical practice faces considerable challenges. Current knowledge remains fragmented across molecular mechanisms, preclinical models, and clinical trials. A systematic, integrative framework linking circadian dysfunction in PD from pathogenesis to therapeutic application is lacking. Furthermore, clinical studies of chronotherapy often suffer from methodological inconsistencies, including non-standardized protocols, inadequate personalization for individual chronotypes, and a lack of consideration for the temporal dimension in drug efficacy and side effect profiles. This oversight may partly explain the suboptimal and variable responses observed in some trials. This review aims to synthesize the current evidence on circadian dysregulation in PD and evaluate the potential of chronotherapy. We will traverse the journey from molecular mechanisms and cellular pathophysiology to preclinical evidence and clinical trial outcomes. By integrating these disparate strands of research, this article seeks to provide a cohesive roadmap that highlights both the compelling rationale for circadian-based interventions and the pragmatic challenges in their implementation. Our goal is to articulate a clear vision for integrating chronobiology into personalized PD management, thereby informing future research directions and advancing towards more effective, timing-optimized therapeutic strategies. The concept of chronobiology: timing as a fundamental dimension in physiology and disease Circadian rhythms are endogenous, self-sustained 24 h oscillations that have evolved to synchronize with Earth’s rotational cycle13. Halberg and Stephens formally introduced this term in 1964, and decades later, the conceptual framework gained prominence in scientific research14. An important development was the 2017 Nobel Prize in Physiology or Medicine, which recognized pioneering research that elucidated the molecular basis of these widespread biological rhythms15. In mammalian systems, circadian dynamics operate through a hierarchical regulatory architecture. The hypothalamic suprachiasmatic nucleus (SCN) serves as the master pacemaker, tasked with coordinating temporal harmony across the entire organism. Central to the SCN’s functionality is its ability to lock onto environmental light cues16. Intrinsically photosensitive retinal ganglion cells (ipRGCs), which express the photopigment melanopsin, detect light and relay signals via the retinohypothalamic tract to entrain SCN neuronal activity17. From this central command center, the SCN disseminates temporal cues to peripheral clocks scattered throughout all tissues. The molecular scaffolding of circadian rhythms relies on the interplay between transcriptional-translational feedback loops (TTFLs) and non-transcriptional regulatory mechanisms18. At the heart of TTFLs are Brain and Muscle ARNT-Like Protein 1 (BMAL1)-Circadian Locomotor Output Cycles Kaput (CLOCK) heterodimers, which translocate to the nucleus, bind to E-box elements in clock-controlled gene promoters, and trigger Period (PER) and Cryptochrome (CRY) transcription19. Accumulated PER/CRY proteins form cytoplasmic heterodimers that migrate back to the nucleus, repressing BMAL1-CLOCK-mediated transcription to form the negative feedback loop underlying circadian oscillation20. Molecular clocks govern a wide range of physiological outputs: brain neural activity, systemic energy metabolism, immune cell effector functions, and rhythmic hormone secretion. Modern living—characterized by shift work, transmeridian jet lag, and irregular eating habits—has emerged as a major threat to circadian homeostasis21. It decouples internal clocks from environmental light-dark cycles, triggering a cascade of deleterious biological effects22. Chronotherapy offers two complementary strategies to counteract this misalignment: (i) zeitgeber-based interventions (e.g., timed light exposure, physical activity, normal scheduling) aimed at restoring disrupted circadian rhythms, and (ii) chronopharmacology, which schedules drug administration to align with endogenous rhythms to optimize efficacy and minimize side effects23. Both approaches leverage the circadian system to improve health outcomes. Circadian dysregulation in PD: from pathogenesis to progression α-Synuclein dynamics and circadian rhythms PD pathogenesis is tightly linked to circadian dysregulation, especially in the temporal control of α-syn metabolism24,25. α-syn dynamics (not just a static pathological hallmark) are governed by a precise circadian network, where both synthesis and clearance of misfolded aggregates are orchestrated by core clock molecules26. The Synuclein Alpha gene (SNCA, encoding α-syn), a core hub connecting PD and circadian rhythms, contains conserved elements in its promoter that may bind the BMAL1-CLOCK heterodimer27.BMAL1-CLOCK enhances SNCA transcription during the active phase, while PER1/2 and CRY1/2 (negative feedback loop components) inhibit BMAL1-CLOCK in the resting phase, suppressing α-syn synthesis28–30. Misfolded α-syn clearance is also circadian-controlled, relying on the glymphatic pathway and ubiquitin-proteasome system (UPS) (both rhythmic with the sleep-wake cycle)30–32. The glymphatic pathway—comprising astrocyte endfoot Aquaporin-4 (AQP4) channels, perivascular spaces, and cerebrospinal fluid (CSF)-interstitial fluid (ISF) exchange networks—functions more robustly during Non-Rapid Eye Movement (NREM) sleep32. AQP4 (key for glymphatic transport) shows circadian oscillations in membrane localization and expression, directly regulated by BMAL1; BMAL1 deficiency impairs AQP4 polarization to astrocyte endfeet, reducing clearance efficiency31,33. Additionally, the UPS (for misfolded protein degradation) is regulated by clock-controlled genes (UBB and USP2, encoding ubiquitin-conjugating and deubiquitinating enzymes, respectively), whose expression peaks during sleep to facilitate α-syn degradation32. Circadian disruption as a multifaceted contributor of PD pathogenesis Circadian disruption is an active contributor of PD neurodegeneration, mediated by interconnected molecular networks centered on core clock machinery. Studies show decreased nuclear BMAL1, reduced PER2 expression, and dysregulated Nuclear Receptor Subfamily 1 Group D Member 1 (REV-ERBα)/Retinoid-Related Orphan Receptor Alpha (RORα) balance in the substantia nigra and cortex of PD patients and models34,35; these abnormalities disrupt rhythmic transcription of clock-controlled genes (CCGs; involved in metabolism, inflammation, and barrier function), laying the molecular foundation for pathological cascades35. Circadian disruption induces chronic neuroinflammation via the RORα-dependent pathway36. Microglia (central nervous system (CNS) resident immune cells expressing core clock genes) have their M1/M2 polarization balance tightly controlled by the circadian clock37. Physiologically, RORα (clock auxiliary loop component) binds anti-inflammatory gene promoters to maintain M2 dominance in the resting phase38. Under disruption, reduced RORα weakens anti-inflammatory gene activation and activates the NF-κB pathway, upregulating TNF-α, IL-6, and iNOS39. Melatonin (a circadian regulator) binds RORα’s ligand-binding domain, enhancing its competition with REV-ERBα for Retinoic acid receptor-related orphan receptor response element‌ (RORE) sites to restore anti-inflammatory gene expression and shift microglia to M240. Disruption of this “clock-RORα-microglial polarization” axis causes persistent microglial activation and excessive pro-inflammatory factors, inducing oxidative stress and apoptosis in dopaminergic neurons41. Circadian disruption also impairs blood-brain barrier (BBB) integrity by disrupting neurovascular unit (NVU) rhythmicity42,43. The BBB (a conserved circulatory-CNS barrier) relies on stable tight junction proteins (CLAUDIN-5, OCCLUDIN, ZO-1) between brain microvascular endothelial cells (BMECs)—regulated by the circadian clock44,45. The BBB has an autonomous clock: CLOCK/BMAL1 binds E-box elements in CLD5/TJP1 promoters to drive diurnal permeability oscillations (daytime xenobiotic efflux, nighttime enhanced endocytosis)46. In PD with circadian disruption, reduced BMAL1 in BMECs decreases rhythmic transcription of tight junction proteins, impairing BBB integrity47. This allows peripheral pro-inflammatory factors/neurotoxins to enter the CNS and disrupts α-syn/metabolic waste clearance, forming a “barrier damage-pathology exacerbation” cycle. Neurotransmitter systems under circadian control PD-related neurotransmitter dysfunction is precisely regulated by core circadian mechanisms, with clock gene-neurotransmitter pathway interactions as key drivers. Dopamine (critical for motor and mood regulation) has its DRD2 receptor gene as a direct circadian target: CLOCK/BMAL1 induces DRD2 transcription time-dependently, while PER/CRY represses it to maintain rhythmicity48. Clock-driven DRD2 rhythmicity modulates downstream tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and dopamine transporter (DAT) via the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) pathway, ensuring diurnal dopamine oscillation49,50. In PD with circadian disorders, reduced BMAL1 and abnormal PER/CRY oscillation impair DRD2 transcription, perturbing cAMP/PKA signaling51,52. This causes dysregulated TH/DAT expression, reduced dopamine availability during peak demand, and exaggerated fluctuations—providing a mechanistic basis for circadian-dependent neuropsychiatric deterioration and motor fluctuations53,54. Melatonin secretion may be blunted in PD due to impaired pineal clock-dependent pathways55. Melatonin synthesis is strictly circadian: during the dark phase, the core clock inhibits sympathetic suppression of the pineal gland, activating arylalkylamine N-acetyltransferase‌ (AANAT) (rate-limiting enzyme) transcription via CLOCK/BMAL1-E-box binding56. Nighttime AANAT is phosphorylated by PKA, binds 14-3-3, and converts serotonin to N-acetylserotonin (subsequently methylated to melatonin)57; light terminates this by inducing AANAT degradation. Circadian disruption (phase misalignment, reduced BMAL1) downregulates AANAT, decreasing melatonin synthesis58. Beyond serving as a biomarker of circadian disruption, the loss of endogenous melatonin deprives the brain of its neuroprotective effects. Melatonin normally acts via MT1/MT2 receptors and Phosphatidylinositol 3-kinase (PI3K)/Protein Kinase B (Akt)/Extracellular signal-regulated kinase (ERK) pathways to suppress oxidative stress and neuroinflammation (e.g., TNF-α, IL-6)59; its absence therefore removes this brake, further exacerbating dopaminergic neuron degeneration and promoting PD progression. These interconnected circadian regulatory mechanisms in PD are summarized in Fig. 1. Schematic of Circadian Regulation in PD. This figure illustrates the dichotomous regulation of neurophysiological processes by the core molecular clock. Central: The circadian rhythm is driven by the CLOCK/BMAL1 transcriptional activator (active phase) and the PER/CRY repressive complex (rest phase); Left (Active Phase): CLOCK/BMAL1 binds to E-box elements to drive the transcription of SNCA, promoting α-synuclein synthesis. Meanwhile, it regulates dopaminergic transmission via DRD2 expression, and maintains Blood-Brain Barrier (BBB) integrity through rhythmic control of efflux transporters; Right (Rest Phase): Neuroprotective clearance and repair mechanisms are maximized. The glymphatic system facilitates the clearance of α-synuclein aggregates, dependent on BMAL1-regulated AQP4 polarization at astrocyte endfeet. Simultaneously, the Ubiquitin-Proteasome System (UPS) (via Ubb/Usp2) peaks to degrade misfolded proteins. Immunologically, the clock-regulated RORα pathway, reinforced by Melatonin (synthesized by activating arylalkylamine N-acetyltransferase (AANAT)), promotes an anti-inflammatory microglial M2 phenotype, suppressing TNF-α and oxidative stress. Chronotherapy in PD: evidence from bench to bedside Preclinical studies: lessons and caveats from animal models Preclinical models have been pivotal in establishing causal links between circadian disruption and PD pathology, while also uncovering notable inconsistencies rooted in circadian rhythm regulation52. For instance, findings on BMAL1 function diverge sharply across PD models: BMAL1 deletion exacerbates dopaminergic neuron loss in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice51, likely because MPTP activates the NF-κB pathway—whose rhythmic activation is tightly controlled by BMAL1—and BMAL1 loss disrupts the circadian suppression of proinflammatory cytokines (e.g., TNF-α, IL-1β) in microglia52. In contrast, BMAL1 knockout in α-syn overexpression models causes minimal pathological changes, possibly due to compensatory activation of the Neuronal PAS Domain Protein 2 (NPAS2)-CLOCK complex, which maintains partial rhythmic control over α-syn aggregation60. Discrepancies in REV-ERBα-targeted interventions also have circadian-related molecular underpinnings61. Timed REV-ERBα antagonism rescues “sundowning syndrome” in PD mice by restoring the rhythmic output of the SCN and normalizing the diurnal oscillation of astrocyte glial fibrillary acidic protein (GFAP)61. However, it fails to improve motor deficits in α-syn pre-formed fibril injection models, as microglial REV-ERBα rhythmically regulates autophagy-related genes (e.g., Atg5, Beclin1) critical for α-syn clearance, and antagonism disrupts the peak-phase autophagic activity essential for fibril degradation62. While these inconsistencies are partially attributed to unstandardized experimental timing (e.g., single detection time points), they reveal a core therapeutic principle: key PD pathological processes (neuroinflammation, microglial/astrocyte functions, α-syn clearance) are inherently under robust circadian control. Specifically, BMAL1 modulates microglial inflammatory responses by binding to cytokine gene promoters to regulate their rhythmic transcription63; α-syn clearance relies on circadian-dependent autophagic pathways, where core clock genes like Per2 control autophagy-related gene expression and the critical Microtubule-associated protein light chain 3 (LC3)-I/II conversion step for autophagosome formation64. These insights provide a precise mechanistic basis for chronotherapy, emphasizing that controlling and reporting Zeitgeber Time (ZT) is imperative to enhance the reliability and translatability of preclinical findings. Clinical observations and trials Light therapy: from observational correlation to clinical intervention The link between environmental light (the primary zeitgeber) and PD symptoms has evolved from observational correlation to clinical intervention, with distinct molecular pathways underlying its effects. Light acts mainly via melanopsin (OPN4)-expressing retinal ganglion cells that transmit signals to the SCN for circadian synchronization65. Preclinical studies have begun to dissect the molecular mechanisms through which light may influence PD pathology, revealing cell-type-specific effects that mirror the heterogeneity of clock gene interventions66. For example, in animal models, 40-Hz flickering light transiently activates the microglial NF-κB pathway (rhythmically controlled by core clock genes), triggering cytokines (e.g., M-CSF, IL-6) to enhance microglial recruitment and α-syn phagocytosis67. Similarly, green light may upregulate the CLOCK/BMAL1 complex in pinealocytes68, and may also influence the rhythmic expression of GFAP in astrocytes, potentially improving metabolic support for dopaminergic neurons and reducing neuroinflammation69. Preclinical studies have also shown that light therapy enhances dopamine neuron mitochondrial function via cytochrome c oxidase, boosting ATP production and mitigating oxidative stress-induced loss—an effect blunted in neurons with pre-existing α-syn-related mitochondrial damage70. Clinical evidence for light therapy in PD comprises a diverse set of trials with varying designs and outcomes. A widely cited randomized controlled trial (RCT) by Videnovic examined timed polychromatic light in patients with mild-to-moderate PD; although the primary outcomes (sleep efficiency, daytime sleepiness) did not differ significantly between the active and control conditions, exploratory analyses suggested a modest increase in deep N3 sleep duration71. In a controlled exploratory trial, Willis found that continued polychromatic light exposure (3000 lux, evening administration) significantly improved MDS-UPDRS scores (12-point reduction, p = 0.028), sleep quality (The Epworth Sleep Scale (ESS) score reduction, p = 0.013), and nonmotor symptoms (depression, anxiety) in PD patients with prior light therapy experience, whereas red light or treatment withdrawal led to symptom deterioration72. Other RCTs have reported more limited effects: Rutten observed that bright light therapy (10,000 lux) did not outperform low-intensity control light in reducing depressive symptoms, though it modestly improved subjective sleep quality (p = 0.04) via cortisol reduction73; a crossover trial using a head‑mounted device showed no overall improvements in anxiety, depression, or fatigue, but a subgroup with baseline ESS > 11 exhibited reduced daytime sleepiness (p = 0.035)74. Pilot studies have also explored niche applications, such as near-infrared light-mediated reduction of α-synuclein aggregation through enhanced autophagy, a process similar to preclinical circadian-dependent clearance mechanisms75, and evening bright light therapy (5000 lux, 3 months) improving sleep‑related outcomes (Parkinson’s Disease Sleep Scale-2 (PDSS-2) score reduction, p = 0.038) in Japanese PD patients10. A critical challenge lies in the heterogeneity of study protocols, which complicates cross-study comparisons. Key parameters vary widely: light intensity ranges from 950 lux (placebo) to 10,000 lux (active treatment)71,73; spectra include polychromatic light71,72, blue-enriched light74, and near-infrared light75; administration timing spans morning‑only (30 min/d, 7500 lux)76, twice‑daily (morning/afternoon, 10,000 lux)71, and evening (19:00–21:00, 5000 lux)10, with many protocols lacking physiological justification for timing based on circadian phase alignment. For example, twice‑daily light exposure—used in some trials71—contradicts the circadian entrainment principles derived from seasonal affective disorder research, as erratic timing may disrupt SCN synchronization rather than enhance it. Additionally, the balance between beneficial and potentially pro‑inflammatory effects of light may depend on disease stage and individual circadian profiles: excessive blue light has been suggested to overactivate microglial NF‑κB in advanced PD77, while polychromatic light appears more tolerable and effective in improving motor/non‑motor symptoms compared to monochromatic blue light72. These observations underscore the need for standardized, chronotype‑guided protocols that account for disease severity, prior light exposure history, and circadian phase (e.g., evening administration for phase‑advanced PD patients)10. Neurotransmitter-based and neuromodulatory chronotherapy Beyond dopamine and environmental cues, chronotherapies targeting circadian-regulated systems have garnered increasing clinical interest. Rapid eye movement sleep behavior disorde r(RBD), a common prodromal feature of PD, is closely linked to circadian dysfunction. A portion of patients with isolated RBD exhibit blunted melatonin secretion and altered core body temperature rhythms78. A 34-patient RCT showed nightly 2 mg prolonged-release melatonin for 12 weeks improved objective sleep efficiency and reduced circadian misalignment in mild-to-moderate PD12. Agomelatine (a melatonin MT1/MT2 agonist with 5-Hydroxytryptamine Receptor 2C‌ (5-HT2C) antagonism) alleviated PD-related depression and restored diurnal oscillations of BMAL1 and Per2 in patients’ peripheral blood mononuclear cells (PBMCs)79. Mechanistically, melatonin suppresses microglial NF-κB-driven neuroinflammation80 and activates nuclear factor erythroid 2-related factor 2 (NRF2)/antioxidant response element (ARE) antioxidant pathways in dopaminergic neurons81. However, clinical evidence for melatonin in PD remains contentious. A pooled analysis of five RCTs found that while melatonin improved subjective sleep quality (Pittsburgh Sleep Quality Index (PSQI): mean difference (MD) = −1.88), it failed to demonstrate benefits on objective polysomnographic measures or RBD symptoms78, with no improvement in motor symptoms or quality of life78,82. Another meta-analysis confirmed that only short-term (<= 4 weeks) and immediate-release formulations improved PSQI scores83. Thus, positive signals on subjective sleep quality have not translated into consistent objective or long-term clinical benefits. Several chronobiological and clinical factors may contribute to these discrepant findings, many of which have not been adequately addressed. First, genetic subtypes of PD may influence responsiveness: ~85% of PD cases are sporadic; known pathogenic mutations occur in < 2% of the PD population84, yet no RCT has stratified by genetic background. Second, sleep disorder subtypes are often treated as monolithic—at least two distinct brain-clinical biotypes in isolated RBD exist with divergent circadian regulatory capacities85. Third, disease stage modifies response: positive effects in mild-to-moderate PD12 may not generalize to advanced stages due to impaired MT1/MT2 expression. Fourth, normal aging reduces melatonin secretion by 10–15% per decade and fragments circadian rhythms83; no trial has controlled for baseline circadian phase (e.g., dim light melatonin onset) when determining administration timing. Mistimed administration may thus be suboptimal. Collectively, these considerations suggest inconsistent evidence stems partly from neglect of chronobiological variables. Future trials should incorporate genetic profiling, circadian phase assessment, RBD biotype classification, and individualized timing. At present, the balance of evidence does not support melatonin as a standard adjunctive therapy for PD. Timing principles also revolutionize deep brain stimulation (DBS)-based neuromodulation. A prospective study of 6 subthalamic nucleus DBS (STN-DBS) patients found subthalamic local field potential beta activity displays diurnal rhythms increased beta power during the day and decreased beta power during the night, correlating with motor symptom fluctuations86. Another RCT showed closed-loop circadian-adaptive DBS (adjusting intensity to real-time beta rhythms) reduced motor fluctuations by 29% and in stimulation time by 56% vs. conventional continuous stimulation87. This may stem from STN-DBS modulating rhythmic γ-aminobutyric acid (GABA)/glutamate release in the basal ganglia88, with timed stimulation aligning with peak CLOCK/BMAL1 activity to enhance brain-derived neurotrophic factor (BDNF) and postsynaptic density protein 95 (PSD95) in dopaminergic neurons89,90. Notably, DBS efficacy is target-specific: globus pallidus internus DBS (GPi-DBS)’s therapeutic window correlates with striatal dopamine turnover rhythms (distinct from STN-DBS), emphasizing the need to account for individual circadian profiles and target selection91. The major clinical findings from these chronotherapeutic interventions are summarized in Table 1. Table 1Summary of Clinical Evidence for Chronotherapeutic Interventions in PDIntervention CategoryStrategyFindingsEvidence LevelLimitationsRecommended Stage of ApplicationReferencesLight TherapyTimed polychromatic light therapy.Primary outcome measures did not reach statistical significance; exploratory analyses suggested potential benefits on certain sleep metrics, particularly deep N3 sleep.I (RCT)Unstandardized parameters; excessive blue light may overactivate microglial NF-κB, exacerbating inflammation in advanced PD.Mild-to-moderate PD, personalized based on individual chronotype.71Evening polychromatic light (3000 lux, 1 h).Significant improvement in MDS-UPDRS (12-point reduction, p = 0.028), PDQ-39 (10 points, p = 0.011), and ESS (4 points, p = 0.013) in patients with prior light therapy experience.II (Controlled exploratory trial)Small sample size; short duration; patients were not treatment-naïve.PD patients already established on light therapy; evening administration may benefit those with phase-advance.72Morning and evening bright light (10,000/200 lux).Not superior to control light for depression (HDRS). Subjective sleep quality improved more in BLT group (p = 0.04), with a decrease in total cortisol secretion.I (RCT)High placebo response; control light (200 lux) may have had some therapeutic effect.Patients with PD and major depressive disorder; may improve subjective sleep quality and cortisol profiles.73Morning light via head-mounted device (blue-enriched, 45 min).No overall improvement in anxiety, depression, or fatigue. Subgroup with baseline ESS > 11 showed reduced daytime sleepiness (p = 0.035).I (RCT, crossover)Small sample size; most patients had normal baseline HADS and ESS scores.PD patients with excessive daytime sleepiness (ESS > 11); potential for improved compliance with a wearable device.74Near-infrared light.Reduced α-syn accumulation via enhanced autophagy, similar with preclinical circadian-dependent α-syn clearance mechanisms.III (Pilot Study)Early-stage research; optimal dosing and protocol not yet defined.To be determined; potentially applicable for stages with significant α-syn pathology.75Evening bright light (5000 lux, 1 h, 3 months).Significant improvement in PDSS-2 score (p = 0.038). Improvement correlated with a delay in peripheral circadian phase, indicating circadian restoration.II (Prospective study)Small sample size; subjective sleep scales used.PD patients with sleep problems, particularly those receiving dopaminergic therapy.10Morning bright light (7500/950 lux, 30 min).Significant improvement in tremor, UPDRS I, II, IV, and depression scores in active group. ESS improved in both groups.I (RCT, pilot)Short duration (15 days); mild patient population; absolute changes were moderate.Exploratory; may be more effective in more advanced patients with longer treatment.76Neurotransmitter-Based ChronotherapyNightly prolonged-release melatonin (2 mg).Improved objective sleep efficiency by 18.4%.I (RCT)Low-dose (1–2 mg) failed in advanced PD with severe Lewy body pathology, likely due to impaired MT1 expression in the SCN.Mild-to-moderate PD for improving sleep efficiency and circadian alignment.12Melatonin (oral, 2–10 mg, 4–12 weeks).Significant improvement in subjective sleep quality (PSQI: MD = −1.88, p = 0.002) and non-motor symptoms (NMSS). No significant effect on objective sleep measures, motor symptoms (UPDRS-III), or quality of life (PDQ-39).I (Meta-analysis of RCTs)Heterogeneity in dosing and duration; effect on objective sleep parameters remains inconclusive; lack of long-term data.Adjunctive therapy for improving subjective sleep quality and non-motor symptoms in PD patients with sleep disorders.78Agomelatine (melatonin MT1/MT2 agonist with 5-HT2C antagonism).Alleviated PD-related depression and restored diurnal oscillations of BMAL1 and Per2 in PBMCs.II (Multicenter Study)Response heterogeneity exists; additional effects from 5-HT2C antagonism must be considered.PD patients with comorbid depression; may aid in mood and systemic rhythm synchronization.79Melatonin (exogenous).Associated with favorable effects on UPDRS Part I, PSQI, BDI, BAI, and markers of oxidative stress/inflammation. Demonstrated antioxidant and immunomodulatory properties, potentially reducing neuronal death.III (Systematic review)Limited number of high-quality studies; heterogeneous outcomes and small sample sizes; no consistent effect on REM behavior disorder.May serve as an adjunctive antioxidant and anti-inflammatory strategy, particularly for improving sleep-related non-motor symptoms.82Melatonin (dose >4 mg vs. ≤ 4 mg; immediate-release vs. prolonged-release).Doses >4 mg (MD = −2.90) and immediate-release formulations (MD = −2.20) significantly improved PSQI scores. Short-term use (4 weeks) improved PSQI (MD = −2.43), while longer treatment did not. Modest reduction in daytime sleepiness (ESS: MD = −0.97).I (Meta-analysis of RCTs)Limited number of studies for subgroup analyses; variable treatment durations; prolonged-release data remain limited.Short-term (4 weeks) treatment with immediate-release melatonin (>4 mg/day) may be considered for sleep quality improvement in PD.83Neuromodulatory ChronotherapyConventional STN-DBS.Subthalamic local field potential beta activity displays diurnal rhythms, correlating with motor symptom fluctuations.II (Prospective Study)Conventional continuous stimulation is not rhythm-optimized, potentially inefficient.Provides physiological rationale for developing closed-loop, circadian-adaptive DBS.86Closed-loop circadian-adaptive DBS.Reduced motor fluctuations by 29% and total stimulation time by 56% vs. conventional continuous stimulation.I (RCT)Efficacy is target-specific; requires accounting for individual circadian profiles and target selection.Patients with STN-DBS experiencing motor fluctuations, based on real-time circadian physiology signals.87PD Parkinson’s disease, RCT randomized controlled trial, PBMCs peripheral blood mononuclear cells, N3 non-rapid eye movement sleep stage 3, MDS-UPDRS Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale, ESS Epworth Sleepiness Scale, HDRS Hamilton Depression Rating Scale, BLT bright light therapy, PDSS Parkinson’s Disease Sleep Scale, PSQI Pittsburgh Sleep Quality Index, 5-HT2C 5-hydroxytryptamine (serotonin) receptor 2C, BDI Beck Depression Inventory, BAI Beck Anxiety Inventory, MD mean difference, STN-DBS subthalamic nucleus deep brain stimulation. Summary of Clinical Evidence for Chronotherapeutic Interventions in PD PD Parkinson’s disease, RCT randomized controlled trial, PBMCs peripheral blood mononuclear cells, N3 non-rapid eye movement sleep stage 3, MDS-UPDRS Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale, ESS Epworth Sleepiness Scale, HDRS Hamilton Depression Rating Scale, BLT bright light therapy, PDSS Parkinson’s Disease Sleep Scale, PSQI Pittsburgh Sleep Quality Index, 5-HT2C 5-hydroxytryptamine (serotonin) receptor 2C, BDI Beck Depression Inventory, BAI Beck Anxiety Inventory, MD mean difference, STN-DBS subthalamic nucleus deep brain stimulation. Mechanisms of chronotherapeutic benefits: hypotheses and models Synergizing with endogenous rhythms BBB permeability and transport functions are tightly governed by the endogenous circadian clock via precise molecular mechanisms. Research in both drosophila and mammals demonstrates that the molecular clock within BBB endothelial cells regulates the efflux of xenobiotics through rhythmic modulation of key transport proteins46,92. In mice, BBB efflux activity has a peak occurring at the end of the resting light period (ZT14.6 on the fit curve) and a trough occurring at the end of the active dark period (~ZT0), but in BMAL1-knockout mice there was more variability and lower mean expression93. The underlying mechanism involves clock-driven transcriptional regulation of transient receptor potential melastatin 7 (TRPM7): the CLOCK/BMAL1 heterodimer binds to the E-box elements in the TRPM7 promoter, driving its rhythmic expression to modulate intracellular magnesium levels, which in turn regulates the membrane localization and activity of efflux transporters (e.g., P-glycoprotein)94. Non-specific overexpression of CLOCK in BBB endothelial cells disrupts this TRPM7-dependent magnesium oscillation, leading to an erratic increase in BBB permeability92. This forms the basis for optimized delivery—a core axis of circadian neuroprotection—whereby aligning CNS drug administration with endogenous efflux rhythms may optimize bioavailability during periods of neuronal vulnerability95, rather than forcing artificial clock gene expression. Beyond BBB transport, chronotherapy synergizes with clock-governed metabolic, cellular repair, and intersystem clock synchronization pathways. The circadian system is intrinsically interlocked with cellular metabolism via core clock genes: PER2 modulates the rhythmic expression of autophagy-related genes (e.g., LC3B, BNIP3)96, while REV-ERBα regulates the oscillation of metabolic enzymes involved in energy homeostasis97. Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) and Nuclear respiratory factor 1 (NRF1) are antioxidant enzymes regulated by BMAL198, which exemplifies this link—disrupted PGC-1α and NRF1 rhythmicity may exacerbate oxidative stress in PD. In contrast, timed melatonin administration enhances glymphatic activity via PER2-dependent AQP4 polarization (key to Enhanced Clearance & Repair)99, and may reinforce SCN by upregulating BMAL1, correcting SCN dysfunction common in PD100. Clock gene intervention outcomes also exhibit cell-type specificity, which interacts with Central-Peripheral-Enteric (CPE) Clock Alignment—another critical axis. For instance, microglial-specific REV-ERBα knockout exacerbates neuroinflammation in AD mice, while astrocyte-specific knockout alleviates pathology101,102; similarly, synchronized enterocyte clocks (regulated by REV-ERBα) stabilize the intestinal barrier103, reducing pro-inflammatory leakage and α-syn propagation to the brain104. This intersystem synchronization feeds back to optimize delivery by normalizing hepatic clock-driven expression of drug-metabolizing enzymes105. In conclusion, chronotherapy enhances CNS disease efficacy by leveraging endogenous rhythms to coordinate optimized delivery, CPE clock alignment, and repair mechanisms—avoiding intrinsic clock disruption while maximizing therapeutic targets. Enhancing efficacy and reducing side effects through timing The principle of chronotherapy is temporally separating a drug’s therapeutic effects on target pathways from its off-target toxicity—arbitrary timing may amplify side effects, while rhythm-aligned dosing leverages endogenous physiological oscillations to enhance efficacy and minimize them. In PD, emerging evidence suggests that the pharmacokinetics and pharmacodynamics of dopaminergic therapy exhibit diurnal variation. D2 receptors show diurnal oscillations, with peak sensitivity in the morning and reduced expression in the afternoon106; continued dopamine replacement during the evening downregulation phase may lead to supraphysiological dopamine levels and increase hallucination susceptibility107. Furthermore, levodopa absorption is significantly slower at night than during the day. In a small-scale crossover study, Nyholm et al. found that the time to peak concentration was delayed from 25 minutes (daytime) to 105 min (nighttime), likely due to circadian-dependent gastric emptying108. These observations suggest that aligning levodopa administration with periods of more efficient absorption could reduce motor fluctuations and dyskinesias, although prospective chronotherapy trials are needed to confirm this hypothesis. Outside of PD, the most extensive clinical validation of this principle comes from oncology and cardiovascular medicine, where timed administration has been shown to improve tolerability by aligning drug delivery with circadian rhythms in metabolism and target sensitivity. At the molecular level, the circadian clock governs the rhythmic expression of drug-metabolizing enzymes (e.g., cytochrome P450 enzymes)109,110, a key driver of pharmacokinetic variability and toxicity risk. A study by Ye et al. in 2018 identified clock gene associations with sensitivity to fluorouracil (CRY2, PER1/2, and others) vs. resistance to fluorouracil (NPAS2, CLOCK, and others)111. Moreover, in patients with metastatic colorectal cancer, timed infusion of fluorouracil (morning) and oxaliplatin (afternoon) resulted in a 76% increase in response rate and a 4-fold reduction in toxicity compared to constant infusion, a benefit attributed to circadian rhythms in drug metabolism and cell proliferation112. Non-timed dosing disrupts this balance, causing erratic plasma levels that diminish efficacy or exacerbate toxicity—illustrating the principle that circadian regulation of metabolic enzymes may influence drug bioavailability, a principle that is one of the core principles to the proposed chronotherapy frameworks discussed in this review. It has also been successfully applied in cardiovascular medicine. Bedtime dosing of certain antihypertensives, such as diltiazem, might better control morning blood pressure surges without increasing nocturnal hypotension risks113. Similarly, evening low-dose aspirin more effectively inhibits morning platelet activation by leveraging the circadian peak in cyclooxygenase-1 (COX-1) activity, thereby lowering thrombotic risk with potentially fewer gastrointestinal effects114. These examples illustrate the broader principle that timing-based strategies may enhance therapeutic safety by aligning drug delivery with endogenous physiological rhythms. However, it is important to note that in PD, blood pressure regulation is further complicated by the effects of dopaminergic medications themselves, which may contribute to orthostatic hypotension and labile blood pressure independent of circadian function. Therefore, the direct translation of chronotherapy principles from cardiovascular medicine to PD requires careful consideration of disease-specific factors, including polypharmacy and the nuanced interplay between dopaminergic therapy and cardiovascular regulation. Collectively, these findings support the concept that chronotherapy may reduce side effects through precise alignment with clock-governed metabolic and receptor rhythms, rather than through non-specific dose reduction. While such principles are preliminarily explored and applied in other medical fields, their systematic application in PD remains in its infancy. Nevertheless, these observations provide a conceptual framework for chronotherapy in PD and may serve as a reference for future trials examining the optimal timing of dopaminergic medications in relation to individual circadian profiles. Proposed hypothesis: circadian optimization of neuroprotection In conclusion, we propose an integrative, self-reinforcing hypothesis wherein chronotherapy confers neuroprotection through three mutually regulated axes—Optimized Delivery, CPE Clock Alignment, and Enhanced Clearance & Repair—that form a closed-loop network. The detailed mechanisms underlying this hypothesis, including the bidirectional interactions between axes (e.g., optimized delivery fueling clock alignment, synchronized clocks reinforcing repair, and enhanced repair further improving delivery efficacy), are illustrated in Fig. 2. This model posits that chronotherapy may transform a state of chronic circadian disruption into a self-reinforcing cycle of protection by restoring temporal order across cellular, systemic, and ecological levels. Critically, this approach may target the temporal root of pathological progression, potentially slowing neurodegeneration in diseases such as PD. Hypothetical model: Circadian Optimization of Neuroprotection. This figure illustrates the proposed “Three-Axis Closed-Loop” hypothesis, wherein chronotherapy establishes a self-reinforcing cycle of neuroprotection. Axis 1: therapeutic timing synergizes with the endogenous rhythms of the Blood-Brain Barrier (BBB). The CLOCK/BMAL1 complex drives the rhythmic transcription of TRPM7, which modulates intracellular magnesium levels and subsequently regulates P-glycoprotein (P-gp) efflux activity. Aligning dosing with efflux nadirs maximizes CNS bioavailability; Axis 2: optimized delivery reinforces the Central-Peripheral-Enteric clock network. Synchronization of the SCN with hepatic clocks (regulating CYP3A4 metabolism) and enteric clocks (stabilizing intestinal barriers and microbiota) minimizes systemic inflammation and off-target toxicity by separating peak drug concentrations from peak enzyme activity; Axis 3: systemic synchronization fosters a permissive environment for rest-phase restorative processes. This includes glymphatic clearance of protein aggregates via PER2-dependent AQP4 polarization, antioxidant defense (NRF1 oscillation), and autophagy (LC3B). Furthermore, anti-inflammatory microglial polarization (M2 phenotype) is promoted. The restoration of these physiological rhythms feeds back to the BBB, further optimizing the window for future therapeutic delivery, thereby slowing neurodegenerative progression. Translational challenges and limitations The implementation of chronotherapy in PD is constrained by a series of interconnected scientific, methodological, and practical hurdles that span from basic biology to clinical application. Loss of reliable zeitgebers and heterogeneity in circadian phenotype Natural zeitgebers, evolved over millennia to entrain circadian oscillators to Earth’s 24-hour rotation, have become fragmented in modern lifestyles, disrupting the homeostatic coupling between internal circadian rhythms and external environmental cycles115. These challenges originate from molecular perturbations within the core circadian clock—a conserved regulatory system that orchestrates rhythmic physiological processes, including diurnal rhythms of TH and DAT in PD55. Intrinsic heterogeneity in circadian phenotypes emerges from genetic (e.g., PER2 rs2304672 in PD) and epigenetic variations in core clock genes and age-related remodeling of molecular regulatory networks116,117. Even under standardized environmental conditions, these molecular differences alter TTFL function, leading to distinct circadian profiles among individuals118. When combined with interindividual phenotypic variability, this fragmentation makes the establishment of a universal “normal” circadian phase impractical, creating obstacles to the early stratification of patients with circadian-related disorders like PD. In future, it is essential to define circadian dysfunction using validated biomarkers, accurately quantifying endogenous circadian phase, and developing personalized chronotherapies tailored to individual phenotypic characteristics. Methodological deficiencies in preclinical and clinical research Methodological flaws in preclinical and clinical research create gaps between basic circadian science and clinical translation, undermining circadian-PD interaction studies. These flaws stem from inadequate consideration of circadian timing and standardization in design—key to reproducibility and translatability of PD circadian regulation findings. In preclinical models, core deficiencies include neglect of species-specific circadian timing—interventions in rodents’ inactive phase distort efficacy/toxicity assessments119—and overreliance on constitutive genetic manipulations that fail to recapitulate PD’s circadian perturbations120. Lack of Zeitgeber Time standardization is critical: TH and DAT are tightly circadian-regulated, with TH oscillations driven by CLOCK/BMAL1 and DAT rhythmicity modulated by PER2. PER2 knockout mice showed blunted DAT oscillations altering levodopa metabolism, emphasizing timed assessments121. In clinical research, poor temporal resolution and standardization are prevalent. Most trials ignore administration/assessment timing122; conventional levodopa misaligns with afternoon TH troughs, possibly leaving motor symptoms unmitigated123. Neurological drugs exhibit high failure rates in Phase II/III clinical trials, a phenomenon partially attributable to the neglect of circadian responses124. Side effects may link to circadian targets125. These flaws create a translational gap, sustaining high failure rates of PD disease-modifying therapies126. Future research should prioritize circadian standardization to bridge basic science and clinical application. Limitations of current therapies and barriers to implementation First-line PD pharmacotherapy is time-agnostic. Dopamine replacement therapies (DRT) address neurotransmitter deficits but overlook circadian regulation of the dopaminergic system—CLOCK/BMAL1-driven TH oscillations and rhythmic DAT expression govern dopamine synthesis/clearance127. Fixed levodopa ignores these rhythms and diurnal symptom fluctuations (morning akinesia, afternoon bradykinesia/rigidity), which may raise motor fluctuations/dyskinesia by 42% vs. chronotype-tailored dosing, with suboptimal control128. Implementing validated chronotherapeutics faces practical barriers. Ensuring adherence to personalized regimens (e.g., levodopa matched to TH phases, selective serotonin reuptake inhibitor timing to block evening serotonin transporter peaks) is challenging, especially in cognitively impaired elderly129. Approved PD chronotherapeutics are scarce, with most (timed levodopa, melatonin) used off-label. Novel molecules targeting core clock components (CLOCK/BMAL1, REV-ERBα, PER2) show promise but are in early development35. Circadian phenotype heterogeneity hinders chronotherapy personalization130. Patients vary in chronotype, age, disease stage, subtype, and genetics—e.g., PER2 rs2304672 T allele carriers may have delayed dopamine turnover, possibly requiring later levodopa131. If levodopa is given in the morning, it may increase the risk of developing dyskinesia. Precision chronotherapy requires accessible tools for routine circadian phase monitoring, but it is still an unmet need. Another underexplored dimension is the relevance of chronotherapy for drugs with long half-lives. Conventional pharmacokinetic principles suggest that drugs with half-lives exceeding 24 hours maintain relatively stable plasma concentrations, which might diminish the importance of administration timing132. However, this assumption overlooks the circadian rhythms of drug clearance and target availability. Important processes such as hepatic cytochrome P450 activity, renal excretion, and ABC/SLC transporter functions exhibit strong circadian oscillations, leading to time-dependent variations in drug metabolism and elimination even for long-acting agents133. Consequently, plasma concentrations of long-half-life drugs may be not truly constant but fluctuate rhythmically due to circadian organ function. Furthermore, drugs targeting molecules with endogenous circadian oscillations (e.g. neurotransmitters or hormones) may benefit from chronotherapy. For example, evening statin dosing aligns with the nocturnal peak of cholesterol synthesis, illustrating target-driven timing134. Conversely, for drugs whose targets lack significant circadian variation or whose long half-life dampens concentration fluctuations, the utility of timed administration remains unproven and requires further investigation. Therefore, chronotherapy may not be universally applicable; its potential depends on specific drug-target pairs, clearance pathways, and the strength of circadian regulation in the relevant physiology. Current controversies and evidence gaps Despite growing interest in circadian mechanisms in PD, the overall quality and consistency of evidence remain limited. Clinical studies have yielded conflicting results across interventions, reflecting heterogeneity in study design, patient populations, and the lack of standardized chronobiological protocols. Moreover, much of the mechanistic understanding and therapeutic promise in this field derives from non-PD models (e.g., oncology, cardiovascular medicine, other neurodegenerative diseases) or from preclinical systems that may share certain molecular pathways but may not substitute for direct validation in PD-specific contexts. The paucity of rigorous, PD-focused investigations constrains both the translation of chronotherapy into clinical practice and the elucidation of its underlying mechanisms. Acknowledging these controversies and evidence gaps is essential for framing realistic expectations and guiding future research. Future perspectives: towards precision chronotherapy The future of chronotherapy in PD lies in systematically transforming its current limitations into pillars of a new, precision medicine framework. The path forward necessitates closed-loop, adaptive, and deeply personalized strategies. This evolution will be driven by concurrent advances in three interconnected domains: the objective and granular assessment of circadian health, a fundamental paradigm shift in research methodology, and the strategic redesign of therapeutic interventions themselves. From coarse assessment to high-resolution circadian phenotyping A key methodological advancement for circadian research translation could involve shifting from coarse, low-information assessments to high-resolution, multidimensional circadian phenotyping. This approach draws on well-validated physiological surrogates that may directly reflect core clock function, including core body temperature, blood pressure, heart rate variability (HRV), and electroencephalographic (EEG) signals—all exhibiting robust 24 h rhythmic fluctuations regulated by molecular clock mechanisms135–137. Core temperature oscillations often correlate strongly with melatonin secretion; blood pressure and HRV rhythms may be modulated by clock-controlled autonomic pathways; and EEG-defined sleep architecture tends to align closely with circadian phase shifts135–138. Integrating next-generation wearable and ambient sensing technologies with advanced analytical tools may enable real-time, continuous monitoring of multiple physiological signals, generating large-scale, high-frequency real-world datasets139. A critical challenge in this approach, particularly in PD, lies in disentangling endogenous circadian rhythms from confounding factors. Dopaminergic medications themselves influence blood pressure, heart rate, and autonomic function; polypharmacy adds further variability; and non-circadian factors such as physical activity, mood, and environmental conditions may obscure true rhythmic patterns. To address these challenges, multimodal monitoring—integrating activity, temperature, HRV, and sleep architecture—is essential, rather than relying on any single signal. Machine learning algorithms might then parse these high-dimensional datasets to extract robust circadian signatures while accounting for these confounding variables140, thereby facilitating accurate identification of PD-specific circadian rhythms in real-world settings. Looking forward, this integrated framework may hold transformative clinical translation potential: it could deliver personalized zeitgeber alignment insights, bridge foundational research and clinical practice, and pave the way for shifting from standardized treatments to precision chronotherapy tailored to individual patients’ unique circadian profiles. Methodological reformation: embedding time into the research fabric Clinical trials may improve temporal resolution and standardization by incorporating prospective recording of circadian time (ZT/CT) for all interventions and outcomes. This helps uncover time-dependent effects masked by arbitrary timing, such as diurnal fluctuations in melatonin MT1/MT2 receptor efficacy, which are associated with neuroendocrine and circadian rhythm disturbances141. Circadian-specific interventions like light therapy may benefit from standardized yet personalized protocols, with parameters aligned to molecularly defined chronotypes rather than clock time, which may enhance individualization via molecular phenotyping142,143. Preclinical reform focuses on addressing animal model flaws: rigorous environmental control (standardized 12:12 h light-dark cycles, 22 ± 1 °C temperature, fixed feeding schedules) helps synchronize circadian systems144,145. All interventions and tissue collection should ideally occur at precise ZTs. Methodological advances extend to cellular and organotypic platforms, where recapitulating endogenous circadian rhythms is critical for mechanistic research146. Primary cells and cell lines may achieve circadian synchronization via zeitgeber mimics. Serum shock induces synchronous gene oscillation, while dexamethasone modulates core clock regulators to drive rhythmicity147–149. Circadian synchronization serves as an important foundation for clock gene manipulation, as unsynchronized cells may mask genetic effects—a potential limitation of constitutive models146. PD patient-induced pluripotent stem cells (iPSCs)-derived brain organoids bridge cellular and in vivo systems, recapitulating tissue-level circadian dysregulation25. To maintain rhythms, cultures need zeitgeber cues and pre-experiment synchronization, which enables studies of circadian cell-cell crosstalk and chronotherapy evaluation in systems retaining PD hallmarks150. These reforms aim to replace blunt tools with time-integrated methodologies. Shifting to inducible knockout systems, circadian-responsive clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (Cas9) modulation, and rhythm-regulating agents might precisely mimic PD-associated circadian dysregulation121,151,152. This cross-platform rigor establishes a robust framework for decoding time-dependent mechanisms, uncovering phase-specific drug responses, and narrowing the translational gap that contributes to high failure rates of disease-modifying therapies. Therapeutic innovation: from time-agnostic to time-optimized strategies Addressing PD’s therapeutic limitations requires a paradigm shift from time-agnostic to time-optimized strategies, targeting unmet symptom control, motor fluctuations, and non-motor symptom burdens. Current first-line dopaminergic therapies, with fixed-dose schedules ignoring diurnal fluctuations like morning akinesia, could be chrono-optimized via pharmacokinetic/pharmacodynamic modeling based on individual circadian parameters, improving symptom control and reducing complex motor fluctuations153. To overcome poor adherence and scarce approved chronotherapeutics, an acceleration of development of novel agents targeting core clock components (e.g., REV-ERBα, RORα) and PD-related pathways is needed61,154,155. Smart closed-loop systems—integrating implantable devices, wearable data, and real-time circadian biomarkers—dynamically adjust stimulation or drug release, eliminating the need for complex manual dosing156. These systems capture interindividual heterogeneity in chronotype, age, disease stage, and PD subtype, guiding real-time adjustments156. Aided by validated circadian biomarkers for precise phase monitoring in clinical and home settings, this fulfills the unmet need for robust tools, transforming chronotherapy into a precision modality that adapts dynamically to disease progression and each patient’s biological rhythm. The components and pathways for this transformation are outlined in Table 2. Table 2A Transdisciplinary Research Framework and Tools for Building Precision Chronotherapy in PDCore PillarMajor ComponentsExisting Tools/MethodsTechnologies/Challenges to DevelopExpected OutcomesReferencesHigh-Resolution Circadian PhenotypingUse of physiological surrogates (e.g., core body temperature, blood pressure, HRV, EEG) as indicators of core clock function.Validated physiological signal monitoring (e.g., melatonin assays, ambulatory blood pressure monitoring, polysomnography).Next-generation wearable & ambient sensing technologies for continuous, multi-signal capture.Generation of large-scale, real-world datasets for circadian analysis.Personalized insights for zeitgeber (e.g., light, activity) alignment.135,136Integration of continuous monitoring data for holistic assessment.Collection of real-world activity and sleep data via consumer wearables.Machine learning algorithms to detect fine-grained, PD-specific circadian signatures from complex datasets.Accurate identification of individual circadian disruption patterns.Foundation for shifting from standardized to precision circadian therapies.140Methodological Reformation: Embedding Time into ResearchClinical Trials:Prospective recording of circadian time for all interventions and outcomes.Use of sleep diaries and actigraphy for approximate circadian phase estimation.Standardized protocols that align interventions (e.g., light therapy) to molecularly defined chronotypes, not just clock time.Uncovering time-dependent therapeutic effects (e.g., diurnal variation in drug receptor efficacy).141–143Preclinical Models:Implementation of rigorous environmental control (light-dark, temperature, feeding schedules).Standardized animal housing with 12:12 h light-dark cycles.Development and use of inducible genetic systems for precise, time-controlled manipulation of clock genes.Reduced experimental noise and enhanced reproducibility in animal studies.121,144,145,151,152Cellular/Organoid Models:Recapitulation of endogenous circadian rhythms in vitro.Cell synchronization techniques (serum shock, dexamethasone).Methods to maintain long-term, robust circadian oscillations in complex cultures like iPSCs-derived brain organoids.Better modeling of circadian cell-cell crosstalk in PD-relevant tissue.25,146–150Patient-derived iPSCs brain organoids modeling PD pathology.Validated platforms for screening chronotherapies in a human-relevant system.Therapeutic Innovation: Time-Optimized StrategiesChrono-optimization of existing dopaminergic therapies.Pharmacokinetic/pharmacodynamic modeling.Smart, closed-loop systems that integrate wearable data, circadian biomarkers, and implantable devices for dynamic therapy adjustment.Improved symptom control and reduced motor fluctuations through timed drug dosing.153,156Development of novel agents targeting core clock components.First-line dopaminergic drugs with fixed-dose schedules.Accelerated discovery and validation of novel chronotherapeutic drugs targeting clock pathways.New disease-modifying treatments that target circadian pathogenesis.61,154,155Creation of adaptive, closed-loop neuromodulation and drug delivery systems.Conventional continuous deep brain stimulation.Identification and validation of robust, minimally invasive circadian biomarkers for phase monitoring in clinical and home settings.Dynamic personalization of therapy based on individual circadian phase, disease stage, and progression.156PD Parkinson’s disease, HRV Heart Rate Variability, EEG electroencephalogram. A Transdisciplinary Research Framework and Tools for Building Precision Chronotherapy in PD PD Parkinson’s disease, HRV Heart Rate Variability, EEG electroencephalogram. Conclusion The circadian system governs multiple physiological processes relevant to PD, including drug metabolism, neurotransmitter dynamics, and cellular repair pathways. Incorporating this temporal dimension into therapeutic strategies may help optimize treatment efficacy and reduce adverse effects. A proposed framework—centered on three interconnected axes: Optimized Delivery aligned with blood‑brain barrier rhythms, synchronization of central‑peripheral‑enteric clocks, and enhanced clearance and repair mechanisms—offers a conceptual basis for chronotherapeutic interventions. However, translating chronobiology into clinical practice faces substantial limitations. Evidence from basic research, preclinical models, and clinical trials remains fragmented, partly due to uncontrolled variables and the lack of standardized circadian phase assessment. Unlike animal studies, where environmental conditions may be tightly controlled, human endogenous clocks exhibit marked interindividual variability influenced by genetics, age, disease stage, and lifestyle. Consequently, without reliable methods to measure individual circadian phase, aligning interventions with a patient’s internal rhythm remains speculative, and the true effects of chronotherapy cannot be rigorously evaluated. Addressing this measurement gap—by developing accessible tools for personalized circadian phenotyping—represents a necessary first step. Such an approach may help reconcile inconsistent findings and enable mechanism‑based, rhythm‑guided strategies for PD management. Acknowledgements This work was supported by the Tianjin Science and Technology projects (21JCYBJC00880). Author contributions L.N. conceived the review, formulated the key perspectives, and designed the overall framework. H.L. and H.L. contributed equally as major contributors in writing and organizing the manuscript. K.S. and K.Y. assisted in drafting and revising sections of the text. W.D. and Y.M. were responsible for creating and refining the tables and figures. K.W. and Y.W. performed the literature search, screening, and thematic organization. Y.L. reviewed the manuscript and provided important intellectual feedback. All authors read, revised, and approved the final version of the manuscript. Data Availability Data sharing is not applicable to this article as no datasets were generated or analysed during the current study. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. These authors contributed equally: Hong Liu, Hao Ling. References Associated Data Data Availability Statement Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.